Concepts (277)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cocaine | 71 | 2020 | 355 | 14.210 |
Why?
|
| Cocaine-Related Disorders | 31 | 2020 | 125 | 6.710 |
Why?
|
| Dopamine Uptake Inhibitors | 27 | 2020 | 147 | 5.060 |
Why?
|
| Self Administration | 66 | 2020 | 386 | 4.850 |
Why?
|
| Choice Behavior | 15 | 2020 | 88 | 4.280 |
Why?
|
| Macaca mulatta | 58 | 2020 | 355 | 3.780 |
Why?
|
| Receptors, Dopamine D3 | 13 | 2017 | 33 | 3.540 |
Why?
|
| Receptors, Dopamine D2 | 17 | 2017 | 82 | 3.430 |
Why?
|
| Brain | 22 | 2020 | 1032 | 3.310 |
Why?
|
| Animals | 96 | 2020 | 8579 | 2.980 |
Why?
|
| Reinforcement Schedule | 20 | 2019 | 103 | 2.910 |
Why?
|
| Central Nervous System Stimulants | 10 | 2016 | 85 | 2.660 |
Why?
|
| Positron-Emission Tomography | 19 | 2020 | 177 | 2.270 |
Why?
|
| Dose-Response Relationship, Drug | 32 | 2020 | 755 | 2.260 |
Why?
|
| Conditioning, Operant | 15 | 2015 | 125 | 2.190 |
Why?
|
| Substance-Related Disorders | 10 | 2016 | 140 | 2.150 |
Why?
|
| Behavior, Animal | 19 | 2015 | 303 | 2.010 |
Why?
|
| Dopamine Agonists | 8 | 2014 | 33 | 1.870 |
Why?
|
| Feeding Behavior | 8 | 2020 | 168 | 1.850 |
Why?
|
| Dopamine Antagonists | 9 | 2017 | 31 | 1.650 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 6 | 2011 | 14 | 1.640 |
Why?
|
| Male | 77 | 2020 | 20740 | 1.620 |
Why?
|
| Macaca fascicularis | 21 | 2020 | 549 | 1.530 |
Why?
|
| Benzamides | 9 | 2017 | 60 | 1.480 |
Why?
|
| Methamphetamine | 5 | 2015 | 20 | 1.400 |
Why?
|
| Disease Models, Animal | 16 | 2015 | 1129 | 1.360 |
Why?
|
| Dopamine Agents | 3 | 2015 | 21 | 1.260 |
Why?
|
| Yawning | 4 | 2017 | 8 | 1.150 |
Why?
|
| Dextroamphetamine | 4 | 2013 | 17 | 1.140 |
Why?
|
| Cannabinoids | 2 | 2020 | 55 | 1.090 |
Why?
|
| Hierarchy, Social | 4 | 2016 | 26 | 1.070 |
Why?
|
| Caudate Nucleus | 5 | 2012 | 29 | 1.050 |
Why?
|
| Social Dominance | 4 | 2015 | 24 | 1.040 |
Why?
|
| Cognition | 5 | 2017 | 576 | 0.960 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 6 | 2016 | 112 | 0.920 |
Why?
|
| Sex Characteristics | 4 | 2020 | 182 | 0.920 |
Why?
|
| Behavior, Addictive | 5 | 2016 | 40 | 0.910 |
Why?
|
| Cues | 2 | 2016 | 65 | 0.900 |
Why?
|
| Buspirone | 2 | 2015 | 3 | 0.890 |
Why?
|
| Ethanol | 2 | 2017 | 199 | 0.880 |
Why?
|
| Benzazepines | 5 | 2012 | 25 | 0.870 |
Why?
|
| Methylphenidate | 3 | 2013 | 39 | 0.860 |
Why?
|
| Receptors, Dopamine | 4 | 2012 | 26 | 0.860 |
Why?
|
| Social Behavior | 2 | 2016 | 74 | 0.850 |
Why?
|
| Hallucinogens | 4 | 2008 | 12 | 0.830 |
Why?
|
| Glucose | 8 | 2019 | 194 | 0.830 |
Why?
|
| Putamen | 5 | 2012 | 28 | 0.820 |
Why?
|
| Menstrual Cycle | 3 | 2015 | 68 | 0.800 |
Why?
|
| Sleep | 2 | 2014 | 90 | 0.770 |
Why?
|
| Primates | 11 | 2016 | 130 | 0.760 |
Why?
|
| Cyclohexanols | 2 | 2020 | 22 | 0.750 |
Why?
|
| Food Preferences | 3 | 2020 | 36 | 0.750 |
Why?
|
| Quinoxalines | 2 | 2012 | 13 | 0.720 |
Why?
|
| Nicotinic Agonists | 2 | 2012 | 40 | 0.710 |
Why?
|
| Housing, Animal | 5 | 2015 | 24 | 0.680 |
Why?
|
| Pyridines | 3 | 2017 | 87 | 0.670 |
Why?
|
| Stress, Psychological | 4 | 2020 | 233 | 0.660 |
Why?
|
| Dopamine | 6 | 2014 | 268 | 0.660 |
Why?
|
| Guanfacine | 1 | 2020 | 5 | 0.650 |
Why?
|
| Food | 8 | 2014 | 49 | 0.650 |
Why?
|
| Morpholines | 1 | 2020 | 47 | 0.630 |
Why?
|
| Corpus Striatum | 6 | 2008 | 75 | 0.630 |
Why?
|
| Clonidine | 1 | 2020 | 66 | 0.620 |
Why?
|
| Piperazines | 2 | 2012 | 64 | 0.620 |
Why?
|
| Reaction Time | 3 | 2019 | 131 | 0.610 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2019 | 23 | 0.610 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2010 | 95 | 0.610 |
Why?
|
| Amino Acids | 1 | 2019 | 54 | 0.600 |
Why?
|
| Discrimination Learning | 2 | 2011 | 20 | 0.600 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 2 | 2011 | 24 | 0.600 |
Why?
|
| Receptors, Dopamine D1 | 4 | 2010 | 18 | 0.590 |
Why?
|
| Quinpirole | 3 | 2014 | 16 | 0.570 |
Why?
|
| Tropanes | 2 | 2010 | 14 | 0.530 |
Why?
|
| Temperature | 2 | 2007 | 65 | 0.520 |
Why?
|
| Choline | 3 | 2013 | 18 | 0.520 |
Why?
|
| Salicylamides | 2 | 2008 | 4 | 0.520 |
Why?
|
| Motivation | 2 | 2008 | 123 | 0.520 |
Why?
|
| Time Factors | 11 | 2017 | 2353 | 0.510 |
Why?
|
| Progesterone | 2 | 2015 | 112 | 0.500 |
Why?
|
| Social Environment | 4 | 2016 | 82 | 0.500 |
Why?
|
| Nerve Tissue Proteins | 3 | 2012 | 130 | 0.480 |
Why?
|
| Reversal Learning | 2 | 2012 | 5 | 0.470 |
Why?
|
| Drug Administration Schedule | 7 | 2020 | 306 | 0.460 |
Why?
|
| Models, Animal | 2 | 2014 | 198 | 0.450 |
Why?
|
| Environment | 2 | 2013 | 51 | 0.440 |
Why?
|
| Dibenzothiazepines | 1 | 2014 | 1 | 0.430 |
Why?
|
| Reward | 2 | 2016 | 70 | 0.430 |
Why?
|
| Analysis of Variance | 7 | 2015 | 508 | 0.430 |
Why?
|
| Neuropharmacology | 1 | 2014 | 3 | 0.430 |
Why?
|
| Estradiol | 1 | 2015 | 156 | 0.420 |
Why?
|
| Membrane Glycoproteins | 2 | 2004 | 118 | 0.400 |
Why?
|
| Motor Activity | 2 | 2013 | 356 | 0.400 |
Why?
|
| Nicotine | 2 | 2012 | 179 | 0.390 |
Why?
|
| Quinolones | 1 | 2012 | 8 | 0.380 |
Why?
|
| Learning | 4 | 2015 | 88 | 0.380 |
Why?
|
| Nootropic Agents | 1 | 2012 | 14 | 0.370 |
Why?
|
| Antipsychotic Agents | 2 | 2014 | 32 | 0.370 |
Why?
|
| Neostriatum | 3 | 2015 | 29 | 0.370 |
Why?
|
| Autoradiography | 9 | 2015 | 55 | 0.370 |
Why?
|
| Extinction, Psychological | 3 | 2007 | 17 | 0.360 |
Why?
|
| Carbon Radioisotopes | 4 | 2020 | 24 | 0.350 |
Why?
|
| Chromatography, Gas | 1 | 2011 | 3 | 0.350 |
Why?
|
| Memory, Short-Term | 4 | 2015 | 68 | 0.330 |
Why?
|
| Pregnancy, Animal | 1 | 2010 | 20 | 0.320 |
Why?
|
| Exploratory Behavior | 1 | 2010 | 34 | 0.310 |
Why?
|
| Raclopride | 3 | 2008 | 9 | 0.310 |
Why?
|
| Cerebral Cortex | 1 | 2011 | 146 | 0.310 |
Why?
|
| Injections, Intravenous | 4 | 2013 | 102 | 0.310 |
Why?
|
| Cognition Disorders | 1 | 2012 | 390 | 0.300 |
Why?
|
| Female | 12 | 2020 | 21532 | 0.290 |
Why?
|
| Psychopharmacology | 1 | 2008 | 3 | 0.290 |
Why?
|
| Deoxyglucose | 7 | 2015 | 16 | 0.290 |
Why?
|
| Thermogenesis | 1 | 2008 | 5 | 0.280 |
Why?
|
| Thyroxine | 1 | 2008 | 18 | 0.280 |
Why?
|
| 3,4-Methylenedioxyamphetamine | 1 | 2007 | 3 | 0.270 |
Why?
|
| Membrane Transport Modulators | 2 | 2004 | 7 | 0.270 |
Why?
|
| Membrane Transport Proteins | 2 | 2004 | 41 | 0.260 |
Why?
|
| Gyrus Cinguli | 1 | 2007 | 27 | 0.260 |
Why?
|
| Humans | 22 | 2020 | 34562 | 0.260 |
Why?
|
| Limbic System | 2 | 2004 | 16 | 0.260 |
Why?
|
| Fluorenes | 1 | 2007 | 4 | 0.260 |
Why?
|
| Ligands | 4 | 2020 | 97 | 0.260 |
Why?
|
| Fever | 1 | 2007 | 63 | 0.260 |
Why?
|
| Piperidines | 4 | 2010 | 141 | 0.240 |
Why?
|
| Indans | 1 | 2006 | 36 | 0.240 |
Why?
|
| Sex Factors | 3 | 2012 | 708 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2016 | 1393 | 0.220 |
Why?
|
| Amphetamines | 1 | 2004 | 6 | 0.220 |
Why?
|
| Brain Mapping | 4 | 2016 | 208 | 0.210 |
Why?
|
| Models, Psychological | 1 | 2004 | 28 | 0.200 |
Why?
|
| Anesthetics, Local | 1 | 2004 | 96 | 0.190 |
Why?
|
| Psychomotor Performance | 1 | 2003 | 116 | 0.190 |
Why?
|
| Random Allocation | 4 | 2019 | 257 | 0.190 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 3 | 2015 | 10 | 0.180 |
Why?
|
| Follicular Phase | 2 | 2015 | 12 | 0.180 |
Why?
|
| Luteal Phase | 2 | 2015 | 30 | 0.180 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2012 | 58 | 0.180 |
Why?
|
| Fluorine Radioisotopes | 3 | 2010 | 22 | 0.180 |
Why?
|
| Homovanillic Acid | 2 | 2012 | 15 | 0.180 |
Why?
|
| Body Temperature | 2 | 2014 | 23 | 0.170 |
Why?
|
| Temporal Lobe | 2 | 2015 | 35 | 0.170 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2020 | 8 | 0.160 |
Why?
|
| Antigens, Surface | 1 | 2020 | 26 | 0.160 |
Why?
|
| Prodrugs | 1 | 2020 | 17 | 0.160 |
Why?
|
| Radioligand Assay | 2 | 2010 | 26 | 0.160 |
Why?
|
| Microtubules | 1 | 2020 | 22 | 0.160 |
Why?
|
| Quinazolines | 1 | 2020 | 40 | 0.160 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 103 | 0.150 |
Why?
|
| Prefrontal Cortex | 2 | 2015 | 90 | 0.150 |
Why?
|
| Sexual Maturation | 1 | 2019 | 28 | 0.150 |
Why?
|
| Eating | 1 | 2019 | 81 | 0.150 |
Why?
|
| Frontal Lobe | 1 | 2019 | 41 | 0.140 |
Why?
|
| Neural Pathways | 2 | 2016 | 116 | 0.140 |
Why?
|
| Haplorhini | 2 | 2011 | 75 | 0.140 |
Why?
|
| Microglia | 1 | 2019 | 66 | 0.140 |
Why?
|
| Appetitive Behavior | 2 | 2008 | 7 | 0.140 |
Why?
|
| Blinking | 2 | 2010 | 5 | 0.130 |
Why?
|
| History, 21st Century | 2 | 2014 | 63 | 0.130 |
Why?
|
| History, 20th Century | 2 | 2014 | 76 | 0.130 |
Why?
|
| Cercopithecidae | 1 | 2017 | 11 | 0.130 |
Why?
|
| Pregnancy | 2 | 2010 | 1069 | 0.130 |
Why?
|
| Receptors, Cannabinoid | 1 | 2017 | 35 | 0.130 |
Why?
|
| Buprenorphine | 1 | 2016 | 14 | 0.120 |
Why?
|
| Prostatic Neoplasms | 2 | 2013 | 498 | 0.120 |
Why?
|
| Atlases as Topic | 1 | 2016 | 10 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 988 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 74 | 0.120 |
Why?
|
| Spectrophotometry | 1 | 2015 | 22 | 0.110 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2015 | 35 | 0.110 |
Why?
|
| Drug Administration Routes | 1 | 2015 | 14 | 0.110 |
Why?
|
| Hypothermia | 1 | 2015 | 12 | 0.110 |
Why?
|
| Catheters, Indwelling | 1 | 2015 | 44 | 0.110 |
Why?
|
| Thalamus | 1 | 2015 | 39 | 0.110 |
Why?
|
| Recurrence | 3 | 2015 | 296 | 0.110 |
Why?
|
| Administration, Oral | 1 | 2015 | 213 | 0.110 |
Why?
|
| Myelin Proteins | 1 | 2014 | 4 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2016 | 265 | 0.100 |
Why?
|
| Pain | 1 | 2016 | 330 | 0.100 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2014 | 35 | 0.100 |
Why?
|
| Aging | 1 | 2020 | 1010 | 0.100 |
Why?
|
| Phenotype | 1 | 2015 | 657 | 0.100 |
Why?
|
| Behavioral Research | 1 | 2013 | 4 | 0.100 |
Why?
|
| Pharmacology | 1 | 2013 | 6 | 0.100 |
Why?
|
| Rats | 2 | 2012 | 1946 | 0.100 |
Why?
|
| Actigraphy | 1 | 2013 | 15 | 0.100 |
Why?
|
| Androgens | 1 | 2013 | 32 | 0.100 |
Why?
|
| Tomography, Emission-Computed | 2 | 2004 | 29 | 0.100 |
Why?
|
| Drug Partial Agonism | 1 | 2012 | 2 | 0.100 |
Why?
|
| Prostate-Specific Antigen | 1 | 2013 | 63 | 0.100 |
Why?
|
| Dominance-Subordination | 1 | 2012 | 17 | 0.100 |
Why?
|
| Binding Sites | 2 | 2003 | 150 | 0.090 |
Why?
|
| Faculty, Medical | 1 | 2013 | 81 | 0.090 |
Why?
|
| Species Specificity | 1 | 2012 | 101 | 0.090 |
Why?
|
| Fluoxetine | 3 | 2015 | 19 | 0.090 |
Why?
|
| Task Performance and Analysis | 1 | 2012 | 54 | 0.090 |
Why?
|
| Receptors, Nicotinic | 1 | 2012 | 62 | 0.090 |
Why?
|
| Mecamylamine | 1 | 2011 | 11 | 0.090 |
Why?
|
| Nicotinic Antagonists | 1 | 2011 | 17 | 0.090 |
Why?
|
| Deanol | 1 | 2011 | 1 | 0.090 |
Why?
|
| Hydrocarbons, Brominated | 1 | 2011 | 2 | 0.090 |
Why?
|
| Solvents | 1 | 2011 | 6 | 0.090 |
Why?
|
| Quality Control | 1 | 2011 | 49 | 0.090 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 97 | 0.090 |
Why?
|
| Neuropsychological Tests | 1 | 2012 | 372 | 0.080 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2010 | 19 | 0.080 |
Why?
|
| Hippocampus | 1 | 2012 | 225 | 0.080 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 110 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 614 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2367 | 0.070 |
Why?
|
| Magnetoencephalography | 1 | 2009 | 15 | 0.070 |
Why?
|
| Somatosensory Cortex | 1 | 2009 | 30 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 823 | 0.070 |
Why?
|
| Neurons | 1 | 2012 | 491 | 0.070 |
Why?
|
| Injections, Intramuscular | 1 | 2008 | 57 | 0.070 |
Why?
|
| Cerebellum | 1 | 2008 | 27 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2008 | 69 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2009 | 122 | 0.070 |
Why?
|
| Association Learning | 1 | 2007 | 14 | 0.070 |
Why?
|
| Injections, Subcutaneous | 1 | 2007 | 37 | 0.070 |
Why?
|
| Deoxyepinephrine | 1 | 2007 | 2 | 0.070 |
Why?
|
| Serotonin Agents | 1 | 2007 | 6 | 0.070 |
Why?
|
| Haloperidol | 1 | 2007 | 15 | 0.060 |
Why?
|
| Serotonin | 1 | 2007 | 49 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2016 | 260 | 0.060 |
Why?
|
| Lorazepam | 1 | 2006 | 3 | 0.060 |
Why?
|
| GABA Modulators | 1 | 2006 | 9 | 0.060 |
Why?
|
| Disease Progression | 2 | 2009 | 634 | 0.060 |
Why?
|
| Radiography | 1 | 2007 | 397 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 486 | 0.060 |
Why?
|
| Basal Ganglia | 1 | 2005 | 23 | 0.060 |
Why?
|
| Biological Availability | 1 | 2005 | 23 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2005 | 88 | 0.060 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2004 | 18 | 0.050 |
Why?
|
| Stereoisomerism | 1 | 2004 | 28 | 0.050 |
Why?
|
| Association | 1 | 2004 | 5 | 0.050 |
Why?
|
| Vasoconstrictor Agents | 1 | 2004 | 65 | 0.050 |
Why?
|
| Time | 1 | 2004 | 29 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2004 | 74 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2004 | 90 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2008 | 771 | 0.050 |
Why?
|
| Symporters | 1 | 2003 | 13 | 0.050 |
Why?
|
| Septal Nuclei | 1 | 2003 | 16 | 0.050 |
Why?
|
| Mediodorsal Thalamic Nucleus | 1 | 2002 | 5 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2004 | 439 | 0.050 |
Why?
|
| Ventral Tegmental Area | 1 | 2002 | 35 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2003 | 204 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 849 | 0.050 |
Why?
|
| Carbon Isotopes | 3 | 2006 | 10 | 0.040 |
Why?
|
| Social Isolation | 1 | 2002 | 45 | 0.040 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2014 | 76 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2002 | 923 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2002 | 901 | 0.030 |
Why?
|
| Aged | 3 | 2020 | 11022 | 0.030 |
Why?
|
| Tritium | 2 | 2008 | 19 | 0.030 |
Why?
|
| Opioid Peptides | 1 | 2016 | 14 | 0.030 |
Why?
|
| Receptors, Opioid, mu | 1 | 2016 | 36 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 61 | 0.030 |
Why?
|
| Idazoxan | 1 | 2015 | 10 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2015 | 38 | 0.030 |
Why?
|
| Animal Experimentation | 1 | 2014 | 6 | 0.030 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2013 | 7 | 0.020 |
Why?
|
| Kinetics | 1 | 2013 | 259 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2012 | 13 | 0.020 |
Why?
|
| Growth | 1 | 2012 | 7 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2012 | 36 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2012 | 60 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2020 | 3825 | 0.020 |
Why?
|
| Hormones | 1 | 2009 | 26 | 0.020 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2009 | 7 | 0.020 |
Why?
|
| Fingers | 1 | 2009 | 78 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2009 | 139 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 2007 | 46 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 1508 | 0.020 |
Why?
|
| United States | 1 | 2014 | 4278 | 0.010 |
Why?
|
| Protein Binding | 1 | 2005 | 255 | 0.010 |
Why?
|
| Densitometry | 1 | 2004 | 8 | 0.010 |
Why?
|
| Middle Aged | 1 | 2013 | 12726 | 0.010 |
Why?
|